



Applicants: Gregory A. Demopoulos et al. Attorney Docket No.: PH.1.0043.US  
Application No.: 10/760,639 Group Art Unit: 1614  
Filed: January 20, 2004 Examiner: Not yet assigned  
Title: CARDIOVASCULAR COMPOSITIONS AND METHODS USING  
COMBINATIONS OF ANTI-PLATELET AGENTS

INFORMATION DISCLOSURE STATEMENT

Seattle, Washington 98101

November 29, 2004

TO THE COMMISSIONER FOR PATENTS:

Applicant is aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.

1. a. X This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior application No. 10/674,290, filed September 29, 2003, which is a continuation of prior Application No. 10/195,625, filed July 12, 2002, issued as U.S. Patent No. 6,645,168, and is a continuation of U.S. Application No. 09/837,141, filed April 17, 2001, issued as U.S. Patent No. 6,420,432, which is a continuation of U.S. Application No. 09/072,913, filed May 4, 1998, issued as U.S. Patent No. 6,261,279, which is a continuation of U.S. Application No. 08/670,699, filed June 26, 1996, issued as U.S. Patent No. 5,820,583, which is a continuation-in-part of International Application No. PCT/US95/16028, filed December 12, 1995, designating the United States, which is a continuation-in-part of U.S. Application No. 08/353,775, filed December 12, 1994, now abandoned, priority from the filing dates of which is hereby claimed under 35 U.S.C. § 120.
- b. X With exception of reference numbers O19, O54, O68, O88, O100, O168, O633, O950, O971, O972, O1505 which are herewith enclosed for the Examiner's inspection, the references listed on the attached form were submitted to and/or cited by the Patent and Trademark Office in the priority applications and, therefore, are not required to be provided in this application. However, if the Examiner would find it convenient to receive duplicate copies of any of these references, the Examiner is requested to telephone the undersigned attorney.

OMEROS CORPORATION  
1420 Fifth Avenue  
Suite 2600  
Seattle, Washington 98101  
206.623.4688

- c. X Applicants also wish to make known to the U.S. Patent Office the following U.S. Applications that describe and claim subject matter that is similar to the subject matter of this application and rely on the earlier filing dates of the same priority applications identified above. These related applications, as well as any prior art cited therein, may be material to the examination of this application.

U.S. Applications(s):

Application No.	Filing Date	Status
09/839,633	04/20/2001	Pending
10/138,192	05/01/2002	Pending
10/138,193	05/01/2002	Pending
10/180,815	06/25/2002	Pending
10/288,997	11/06/2002	Pending
10/674,290	09/29/2003	Pending
10/915,962	08/11/2004	Pending
10/971,753	10/21/2004	Pending

2. X Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the national application (other than a CPA), within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, before the mailing date of a first Office Action on the merits, or before the mailing date of a first Office Action after the filing of an RCE.
3. X The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.18 which may be required during the entire pendency of the application, or credit any overpayment, to Deposit Account No. 502230. This authorization also hereby includes a request for any extensions of time of the

OMEROS CORPORATION  
1420 Fifth Avenue  
Suite 2600  
Seattle, Washington 98101  
206.623.4688

appropriate length required upon the filing of any reply during the entire prosecution of this application. A copy of this document is enclosed.

Respectfully submitted,

OMEROS CORPORATION



Marcia S. Kelbon  
VP, Patent & General Counsel  
Registration No. 34,358  
Direct Dial No. 206.676.5020

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the below date.

11/29/04  
Date

Sb1-  
Stephanie Jansen

MSK:sj

OMEROS CORPORATION  
1420 Fifth Avenue  
Suite 2600  
Seattle, Washington 98101  
206.623.4688



**INFORMATION CITED BY APPLICANTS THAT MAY BE MATERIAL  
TO THE PROSECUTION OF THE SUBJECT APPLICATION**

Applicants: G.A. Demopoulos et al. Attorney Docket No: PH.1.0043.US  
Serial No: 10/760,639 Group Art Unit: 1614  
Filed: January 20, 2004 Examiner: Not yet assigned  
Title: CARDIOVASCULAR COMPOSITIONS AND METHODS USING  
COMBINATIONS OF ANTI-PLATELET AGENTS

**U.S. PATENT DOCUMENTS**

*Examiner Initial	ID	Document No.	Date	Name
_____	U1	4,504,493	03/12/1985	Marshall et al.
_____	U5	5,051,443	09/24/1991	Neufeld et al.
_____	U6	5,272,139	12/21/1993	Cary
_____	U11	4,872,865	10/10/1989	Bloebaum et al.
_____	U14	4,938,970	07/1990	Hustead et al.
_____	U29	5,512,055	04/30/1996	Domb et al.
_____	U37	5,370,614	12/06/1994	Amundson et al.
_____	U38	5,336,178	08/09/1994	Kaplan et al.
_____	U70	5,744,482	04/28/1998	Cohen et al.
_____	U164	5,800,385	09/01/1998	Demopulos et al.
_____	U165	5,820,583	10/13/1998	Demopulos et al.
_____	U209	5,942,241	8/24/1999	Chasin et al.
_____	U213	5,767,105	06/16/1998	Peyman
_____	U272	5,858,017	01/12/1999	Demopulos et al.
_____	U273	5,860,950	01/19/1999	Demopulos et al.
_____	U274	6,210,394	04/03/2001	Demopulos et al.
_____	U275	6,242,447 B1	06/05/2001	Demopulos et al.
_____	U276	6,254,585 B1	07/03/2001	Demopulos et al.
_____	U277	6,261,279 B1	07/17/2001	Demopulos et al.
_____	U278	6,056,715	05/02/2000	Demopulos et al.
_____	U425	5,523,316	06/24/1996	Gan et al.

_____	U491	6,413,961	07/02/2002	Demopulos et al.
_____	U492	6,420,432	07/16/2002	Demopulos et al.
_____	U553	5,624,893	04/29/1997	Yanni
_____	U646	6,645,168	11/11/2003	Demopulos et al.

## FOREIGN PATENT DOCUMENTS

*Examiner Initial	ID	Document No.	Publication Date	Country	Translation Provided	
					Yes	No
_____	F1	WO 95/16435	06/22/1995	PCT	X	
_____	F2	EP 0,364,266 A2	04/18/1990	European	X	
_____	F7	WO 92/04008	03/19/1992	PCT	X	
_____	F8	EP 0,351,755	01/24/1990	European	X	
_____	F9	WO 95/27482	10/19/1995	PCT	X	
_____	F10	WO 91/04058	04/04/1991	PCT	X	
_____	F16	WO 96/29074	09/26/1996	European	X	
_____	F29	WO 96/26738	09/06/1996	European	X	
_____	F83	EP 0,715,855 A2	06/12/1996	European	X	
_____	F84	EP 0,710,479 B1	01/07/1999	European	X	

## OTHER INFORMATION

(Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner Initial	ID	Document Information
_____	O05	Naesh, O., et al., "Platelet activation in mental stress," <i>Clin. Physiol.</i> <b>13</b> :299-307 (1993).
_____	O06	Evans, R.G., et al., "Effects of 5-HT-receptor and alpha 2-androceptor ligands on the haemodynamic response to acute central hypovolemia in conscious rabbits," <i>Br. J. Pharmacol.</i> <b>109</b> :37-47 (1993).
_____	O13	Willerson, J.T., et al., "Specific Platelet mediators and unstable coronary artery lesions," <i>Circulation</i> <b>80</b> :198-205 (1989).
_____	O19	Moncada et al., "Prostaglandins, Prostacyclin Thromboxane A <sub>2</sub> , and Leukotrienes," Chapter 28, <i>The Pharmacological Basis of Therapy</i> , L.S. Goodman, eds., 1985.
_____	O20	Kessler, W., et al., "Excitation of cutaneous afferent nerve endings in vitro by a combination of inflammatory mediators and conditioning effect of substance P," <i>Exp. Brain Res.</i> <b>91</b> :467-476 (1992).
_____	O23	Levine, J.D., et al., "Desipramine enhances opiate postoperative analgesia," <i>Pain</i> <b>27</b> :45-49 (1986).

- \_\_\_\_\_ O26 Ringkamp, M., et al., "Activated human platelets in plasma excite nociceptors in rat skin, in vitro," *Neurosci. Lett.* **170**:103-106 (1994).
- \_\_\_\_\_ O33 Buzzi, M.G., et al., "5-Hydroxytryptamine receptor agonists for the abortive treatment of vascular headaches block mast cell, endothelial and platelet activation within the rat dura mater after trigeminal stimulation," *Brain Res.* **583**:137-149 (1992).
- \_\_\_\_\_ O37 Schwartz, M.M., et al., "Vascular leakage in the kidney and lower urinary tract: effects of histamine, serotonin and bradykinin," *Proc. Soc. Exp. Biol. Med.* **140**:535-539 (1972).
- \_\_\_\_\_ O39 Serruys, P.W., et al., "Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty; a multicenter randomized double-blind placebo-controlled trial," *Circulation* **88**:1588-1601 (1993).
- \_\_\_\_\_ O40 Cohen, B.M., et al., "Intracoronary cocktail infusion during rotational ablation: safety and efficacy," *Transcatheter Cardiovascular Therapeutics* (1995).
- \_\_\_\_\_ O42 Araki, H., et al., "Longitudinal Propagation of Contraction in the Isolated Conduit Coronary Arteries of Humans and Pigs," *Circulation Research* **64**(4):734-741 (1989).
- \_\_\_\_\_ O43 Berkenboom, G., et al., "Atherosclerosis and responses of human isolated coronary arteries to endothelium-dependent and -independent vasodilators," *J. Cardiovasc. Pharmacol.* **14**:S35-S39 (1989).
- \_\_\_\_\_ O54 Halushka et al., "Thromboxane, Prostaglandin and Leukotriene Receptors," *Annu. Rev. Pharm. Tox.* **10**:213-239 (1989).
- \_\_\_\_\_ O61 Liu, J.J., et al., "Synergistic Effect of Nisoldipine and Nitroglycerin on Human Internal Mammary Artery," *J. Pharmacol. Exp. Therapeutics* **268**(1):434-440 (1994).
- \_\_\_\_\_ O62 Cohen, D.J., et al., "Intraoperative coronary artery spasm successfully treated with nitroglycerin and nifedipine," *Annals of Thor Surg* **36**:97-100 (1983).
- \_\_\_\_\_ O68 Timmermans et al., "Ridogrel in the Setting of Percutaneous Transluminal Coronary Angioplasty," *Am J Cardiol* **68**:463-466 (1991).

- \_\_\_\_\_ O86 Golino, P., et al., "Failure of nitroglycerine and diltiazem to reduce platelet-mediated vasoconstriction in dogs with coronary artery stenosis and endothelial injury: further evidence for thromboxane A<sub>2</sub> and serotonin as mediators of coronary artery vasoconstriction in vivo," *J. Am. Coll. Cardiol.* **15**:718-726 (1990).
- \_\_\_\_\_ O88 Rosolowsky et al., "Synthesis of Lipxygenase and Epoxygenase Products of Arachidonic Acid by Normal and Stenosed Canine Coronary Arteries," *Circulation Research* **66**:608-621 (1990).
- \_\_\_\_\_ O89 DeCaterina, R., et al., "A Double-blind, Placebo-controlled Study of Ketanserin in Patients with Prinzmetal's Angina," *Circulation* **69**:889-894 (1984).
- \_\_\_\_\_ O90 Golino, P., et al., "Divergent Effects of Serotonin on Coronary-Artery Dimensions and Blood Flow in Patients with Coronary Artherosclerosis and Control Patients," *New Engl. J. Med.* **324**:641-648 (1991).
- \_\_\_\_\_ O91 Golino, P., et al., "Local Effect of Serotonin Released During Coronary Angioplasty," *New Engl. J. Med.* **330**:523-528 (1994).
- \_\_\_\_\_ O92 Golino, P., et al., "Endogenous prostaglandin endoperoxides and prostacyclin modulate and thrombolytic activity of tissue plasminogen activator," *J. Clin. Invest.* **86**:1095-1102 (1990).
- \_\_\_\_\_ O93 Ashton, J.H., et al., "Serotonin S<sub>2</sub> and Thromboxane A<sub>2</sub>-Prostaglandin H<sub>2</sub> Receptor Blockade Provide Protection Against Epinephrine-Induced Cyclic Flow Variations in Severely Narrowed Canine Coronary Arteries," *J. Am. Coll. Cardiol.* **13**:755-763 (1989).
- \_\_\_\_\_ O94 Yao, S., et al., "Combined ADP and Thromboxane A<sub>2</sub> Antagonism Prevents Cyclic Flow Variations in Stenosed and Endothelium-Injured Arteries in Nonhuman Primates," *Circulation* **88**:2888-2893 (1993).
- \_\_\_\_\_ O95 Yao, S., et al., "Combination of inhibition of thrombosis and blockade of Thromboxane A<sub>2</sub> synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries," *Circulation* **86**:1993-1999 (1992).
- \_\_\_\_\_ O100 Iwamoto et al., "Differential Vasorelaxant Effects of K<sup>+</sup>-Channel Openers and Ca<sup>2+</sup>-Channel Blockers on Canine Isolated Arteries," *J. Pharm. Pharmacol.* **45**:292-297 (1993).



- \_\_\_\_\_ O114 Podesser, B., et al., "Combined perioperative infusion of nifedipine and metoprolol provides antiischemic and antiarrhythmic protection in patients undergoing elective aortocoronary bypass surgery," *Thorac Cardiovasc Surgeon* **41**:173-179 (1993).
- \_\_\_\_\_ O115 Hannes, W., et al., "Effect of Peri-Operative Diltiazem on Myocardial Ischaemia and Function in Patients Receiving Mammary Artery Grafts," *Europ Heart J* **16**(1):87-93 (1995).
- \_\_\_\_\_ O116 Cohen, B.M., et al., "Cocktail attenuation of rotational ablation flow effects (CARAFE) study: pilot," *Cathet. Cardiovasc. Diagn. Suppl.* **3**:69-72 (1996).
- \_\_\_\_\_ O117 Yao, S.K., et al., "Combined Thrombin Inhibition and Thromboxane A<sub>2</sub> Synthesis and Receptor Blockade Enhances Thrombolysis and Delays Arterial Reocclusion," *Suppl to Journal of the American College of Cardiology, Abstracts 41<sup>st</sup> Annual Scientific Session* **19**(3):329A (1992).
- \_\_\_\_\_ O149 Gyrn, J., et al., "Intra-articular Bupivacaine Plus Adrenoline for Arthroscopic Surgery of the Knee," *Acta Anaesthesiol. Scand.* **36**:643-646 (1992).
- \_\_\_\_\_ O157 Thomas, et al., "The Direct Perfusion of Surgical Wounds with Local Anaesthetic Solution: An Approach to Postoperative Pain?" *Annal R Coll Surg* **65**:226-229 (1983).
- \_\_\_\_\_ O160 Kuga, T., et al., "Inhibitory Effects of Aspirin on Coronary Hyperreactivity to Autacoids After Arterial Balloon Injury in Minature Pigs," *J. Cardiovasc. Pharmacol.* **25**:273-281 (1995).
- \_\_\_\_\_ O168 Yao et al., "ADP and Thromboxane A<sub>2</sub> Are Important Mediators of Cyclic Flow Variations in Nonhuman Primate Arteries," *JACC* **21**(2):110A (1993) (Abstract only).
- \_\_\_\_\_ O171 Golino, P., et al., "Inhibition of Neutrophil Adhesion Proteins Reduces Neointimal Hyperplasia Following Arterial Injury in Rabbit Carotid Arteries," *Am Heart Assoc, Abstracts 67<sup>th</sup> Scientific Sessions* **90**(4)(part 2):I-85 (1994).
- \_\_\_\_\_ O175 Reifart, et al., "Randomized Comparison of Angioplasty of Complex Coronary Lesions at a Single Center," *Circulation* **96**:91-98 (1997).

- \_\_\_\_\_ O176 Yao, S.K., et al., "Endogenously Produced EDRF Protects Against Platelet Aggregation and Cyclic Flow variations in Stenosed and Endothelium-Injured Arteries," *Suppl to Journal of the American College of Cardiology, Abstracts 41<sup>st</sup> Annual Scientific Session* **19(3):376A** (1992).
- \_\_\_\_\_ O177 Liu, M.W., et al., "Intraluminal Alcohol Delivery Reduced Intimal Hyperplasia after Ballon Injury in Pig Coronary Arteries. A Concept of Chemical Atherectomy," *Am Heart Assoc, Abstracts 66<sup>th</sup> Scientific Sessions* **88(4)(part 2):I-655** (1993).
- \_\_\_\_\_ O178 Willerson, J.T., et al., "Pretreatment with Antagonists to Thromboxane A<sub>2</sub>, Serotonin and ADP Reduces Neointimal Proliferation in Canine Coronary Arteries after Endothelial Injury," *J. Am. Coll. Cardiol.* **Incomplete Data:906-32**(1994).
- \_\_\_\_\_ O179 Liu, M. et al., "A Preliminary Report of Local Alcohol Delivery for Treatment of Restenosis within Stented Segments After Successful Caoronary Angioplasty. The Safety Study of Local Alcohol and Stent Against Restenosis (LASAR) Trial." *Joournal of the American College of Cardiology, Abstracts 45<sup>th</sup> Annual Scientific Session* **112A** (1996).
- \_\_\_\_\_ O183 Herrman et al., "Pharmacological Approaches to the Prevention of Restenosis Following Angioplasty," *Drugs* **46:18-52** (1993).
- \_\_\_\_\_ O184 Vahanian et al., "Role of Calcium Channel Blockers in Reducing Acute Ischemia and Preventing Restenosis in PCTA," *Drugs* **52:9-15** (1996).
- \_\_\_\_\_ O185 Narayanan et al., "Recombinant Hirudin: Initial Observations in Reconstructive Microsurgery," *Haemostasis* **21:168-171** (1991).
- \_\_\_\_\_ O187 Gibbons, G.H., et al., "Molecular Therapies for Vascular Diseases," *Science* **272:689-693** (1996).
- \_\_\_\_\_ O188 Jackson, C.L., et al., "Inhibitory effect of calcium antagonists on balloon catheter-induced arterial smooth muscle cell proliferation and lesion size," *Atherosclerosis* **69:115-122** (1988).
- \_\_\_\_\_ O190 Lefkovits, J., et al., "Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention," *Prog. Cardiovasc. Dis.* **40(2):141-158** (1997) (Abstract only).
- \_\_\_\_\_ O219 Allen, G., et al., "Postarthroscopy analgesia with intraarticular bupivacaine/morphine. A randomized clinical trial," *Anesthesiology* **79:475-480** (1993).

- \_\_\_\_\_ O234 Bisla, K., et al., "Concentration-dependent effects of lidocaine on corneal epithelial wound healing," *Invest Ophthalmol. Vis. Sci.* **33**:3029-3033 (1992).
- \_\_\_\_\_ O238 Massey, T., et al., "Serum lidocaine levels during arthroscopy using continuous irrigation with lidocaine," *Clin. Orthop.* **229**:182-184 (1988).
- \_\_\_\_\_ O239 Tsai, L., et al., "Arthroscopic surgery of the knee in local anaesthesia. An analysis of age-related pathology," *Arch. Orthop. Trauma Surg.* **112**:136-138 (1993).
- \_\_\_\_\_ O242 Klein, J.A., "Tumescent Liposuction and Improved Postoperative Care Using Tumescent Liposuction Garments," *Dermatologic Clinics* **13**:329-338 (1995).
- \_\_\_\_\_ O244 Klein, J.A., "The Tumescent Technique Anesthesia and Modified Liposuction Technique," *Dermatologic Clinics* **8**:425-437 (1990).
- \_\_\_\_\_ O246 Ostad et al., "Tumescent Anesthesia with a Lidocaine Dose of 55 mg/kg is Safe for Liposuction" *Dermatol Surg* **22**:921-927 (1996).
- \_\_\_\_\_ O253 Wredmark, et al., "Arthroscopy Under Local Anaesthesia Using Controlled Pressure-Irrigation With Prilocaine," *J Bone Joint Surg* **64**:583-585 (1982).
- \_\_\_\_\_ O367 Talke, P., et al., "Effects of perioperative dexmedetomidine infusion in patients undergoing vascular surgery. The Study of Perioperative Ischemia Research Group," *Anesthesiology* **82**:620-633 (1995).
- \_\_\_\_\_ O633 Börsch-Haubold et al., "Direct Inhibition of Cyclooxygenase-1 and -2 by the Kinase Inhibitors SB 203580 and PD 98059," *The Journal of Biological Chemistry* **273**(44):28766-28772 (1998).
- \_\_\_\_\_ O842 Ben-David et al., "Is Preoperative Ketorolac A Useful Adjunct To Regional Anesthesia For Inguinal Herniorrhaphy?" *Acta Anaesthesiol Scand* **40**:358-363 (1996).
- \_\_\_\_\_ O843 Hyrkäs et al., "Effective Postoperative Pain Prevention Through Administration Of Bupivacaine And Diclofenac," *Anesth Prog* **41**:6-10 (1994).
- \_\_\_\_\_ O844 Glasser et al., "The Perioperative Use Of Corticosteroids And Bupivacaine In The Management Of Lumbar Disc Disease," *J Neurosurg* **78**: 383-387 (1993).

- \_\_\_\_\_ O845 Dionne et al., "Suppression Of Postoperative Pain By The Combination Of A Nonsteroidal Anti-Inflammatory Drug, Flurbiprofen, And A Long-Acting Local Anesthetic, Etidocaine," *JADA* **108**:598-601 (1984).
- \_\_\_\_\_ O950 Bult et al., "Isosorbidedinitrate and SIN-1 as Dilators of Human Coronary Arteries and Platelet Inhibitors," *Journal of Cardiovascular Pharmacology* **25**:572-578 (1995).
- \_\_\_\_\_ O971 Chester et al., "Interaction Between Thromboxane A<sub>2</sub> and 5-Hydroxytryptamine Receptor Subtypes in Human Coronary Arteries," *Circulation* **87**:874-880 (1993).
- \_\_\_\_\_ O972 Willerson et al., "Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury," *Proc. Natl. Acad. Sci. USA* **88**:10624-10628 (1991).
- \_\_\_\_\_ O1505 Reifert et al., "PTCA of Degenerated Vein Grafts: Experience of Two Periods (1992-93 and 1996-97) in 780 Patients," *Indian Heart J* **50(Suppl 1)**:62-66 (1998).

---

Examiner

---

Date Considered

---

\*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MSK:sj



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Gregory A. Demopoulos et al. Attorney Docket No.: PH.1.0043.US  
Application No.: 10/760,639 Group Art Unit: 1614  
Filed: January 20, 2004 Examiner: Not yet assigned  
Title: CARDIOVASCULAR COMPOSITIONS AND METHODS USING  
COMBINATIONS OF ANTI-PLATELET AGENTS

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Seattle, Washington 98101

November 29, 2004

TO THE COMMISSIONER FOR PATENTS:

A. Transmitted herewith are the following:

- X 1. Information Disclosure Statement  
X 2. Citation of Information and 11 references.  
X 3. Small entity status is asserted for this matter.

COMPUTATION OF FEES

	Number Filed	Number Extra	Rate		
Basic Fee					
Total Claims	=	x	9.00	=	0.00
Independent Claims	=	x	44.00	=	0.00
Multiple Dependent Claim Surcharge		+			
Extension of Time		+			
TOTAL					\$0.00

OMEROS CORPORATION  
1420 Fifth Avenue  
Suite 2600  
Seattle, Washington 98101  
206.623.4688

B. Fees Enclosed

☒ No fees are required at this time.

C. Additional Fee Charges or Credit for Overpayment

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.18 which may be required during the entire pendency of the application, or credit any overpayment, to Deposit Account No. 502230. This authorization also hereby includes a request for any extensions of time of the appropriate length required upon the filing of any reply during the entire prosecution of this application. A copy of this document is enclosed.

Respectfully submitted,

OMEROS CORPORATION



Marcia S. Kelbon  
VP, Patent & General Counsel  
Registration No. 34,358  
Direct Dial No. 206.676.5020

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the below date.

11/29/04  
Date

Stephanie Jansen  
Stephanie Jansen

MSK/sj

OMEROS CORPORATION  
1420 Fifth Avenue  
Suite 2600  
Seattle, Washington 98101  
206.623.4688